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Abstract.
Background: Although approximately 75% of bladder cancers are non-muscle invasive (NMIBC) at diagnosis, most research
tends to focus on invasive disease (e.g., experiences related to radical cystectomy and urinary diversion). There is a lack of
studies on quality of life, and especially qualitative research, in bladder cancer generally. As a result, relatively little is known
about the experiences and needs of NMIBC patients.
Objective: To understand patient experience, define care priorities, and identify targets for care improvement in NMIBC
across the cancer continuum.
Methods: Through focus groups, patients treated for NMIBC (stage <T2) were invited to share their care experiences
including diagnosis, treatment, and survivorship. Transcripts were analyzed using conventional content analysis to identify
themes and subthemes.
Results: Twenty patients (16 male, 4 female, all white) participated in three focus groups. Five primary themes emerged:
access to care, provider characteristics and communication, quality of life, goals of care/influences on decision-making, and
role of social support. Patients with NMIBC desired timely access to care and honest and caring provider communication.
They described urinary function and emotional quality of life changes resulting from diagnosis and treatment. Avoiding
cystectomy and being alive for family were the major decision influencers.
Conclusion: In this qualitative study, we identified access to care, provider characteristics and communication, quality of life,
values/influences on decision-making, and social support as priority areas to improve patient experience in NMIBC. Care
redesign efforts should focus on improving access, enhancing provider communication, reducing side effects, and supporting
caregiver roles.
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INTRODUCTION
Bladder cancer is the fifth most commonly diag-
nosed cancer in the United States with over 79,000
new cases diagnosed annually [1]. Most of these
(75–80%) are non-muscle invasive at diagnosis (stage
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<T2) and have relatively low risk of progression to
invasive or metastatic disease (10–20%) [2]. How-
ever, the risk of recurrence is high ranging from
30–70% [3, 4], and there are currently over 600,000
bladder cancer survivors in the United States [5].
Despite the relative rarity of muscle-invasive bladder
cancer, much of current research is directed toward
the treatment of patients undergoing major surgery,
such as radical cystectomy and urinary diversion [6].
As a result, significant gaps remain in our understand-
ing of the needs and overall patient experience in
non-muscle invasive bladder cancer (NMIBC) across
the cancer continuum.
Patient experience is increasingly being recog-
nized as an important metric since its inclusion as
one of the “Triple Aims” for the U.S. health care
system [7]. Poor care satisfaction and experiences
have been associated with outcomes such as lower
health-related quality of life, mental well-being, and
decreased adherence to care [8–10].
A survey comparing the treatment experiences of
all-cause cancer among over 40,000 cancer patients
found that bladder cancer patients have among the
lowest levels of satisfaction with care when compared
to other urologic cancer sites and cancer generally
[11]. Much of current research has focused on quan-
tifying sexual function and health-related quality of
life, which are not fully inclusive of a patient’s expe-
rience through the cancer continuum. Understanding
other aspects of patient experience and care such as
goals of treatment, treatment burden, care processes,
financial toxicity, and caregiver concerns are needed
to redesign care with a patient focus.
Due to the association between patient experience
and outcomes, engaging patients to understand care
processes and experiences across the cancer contin-
uum has been defined as a priority area for multiple
professional organizations and advocacy networks,
particularly in bladder cancer [12, 13]. Qualitative
research methods offer the advantage of directly
engaging patients to share their perspective; how-
ever, exceedingly few qualitative studies pertaining
to NMIBC exist. A recent systematic review identi-
fied fourteen qualitative studies of patient experience
in bladder cancer, and only two were specific to
NMIBC [14].
We designed a qualitative focus group study of
adults with NMIBC to understand patient experience
and define care priorities. We sought to understand
processes across the cancer continuum including
diagnosis, decision-making, treatment, and survivor-
ship.
MATERIALS & METHODS
Study design
In this qualitative study, we conducted three focus
groups with patients from the Geisinger Health Sys-
tem (GHS). The study was reviewed by Geisinger’s
Institutional Review Board and deemed exempt due
to minimal risk.
Setting and participants
Eligible participants were adults 18 years or older
and diagnosed with NMIBC (stage <T2) between
January 2000 and May 2016. Participants were iden-
tified via the GHS Cancer Registry and by screening
urologist clinics. From this list, a random group of eli-
gible participants received a mailed recruitment letter
and a follow-up phone call from a study team mem-
ber. Recruitment was performed from August through
October of 2016. As this was a pilot study with bud-
get limitations, participants were recruited until all
focus group slots were filled.
A total of 87 patients were approached and 20 par-
ticipated in the focus groups. Participants ranged in
age from 46 to 85 years, were 80% male, and were
100% white.
Focus group guide
A semi-structured focus group guide was created
to explore patient experience. Participants were asked
to describe their cancer story starting with how they
found out they had bladder cancer. Subsequent ques-
tions touched on decision-making, goals of care, and
how life has changed since diagnosis (Supplement).
Data Collection
All three focus groups were conducted in
November, 2016, with an average attendance of 7
participants per group. Two focus groups took place
in the evening and one was held in the afternoon.
Groups were conducted in English and lasted 90
minutes. Participants received a catered meal and a
$25 gift card. Each session was audio recorded and
transcribed verbatim by a study team member. All
identifying information was removed from the tran-
scripts to maintain anonymity. All authors except T.G.
assisted in leading the focus groups. T.G. is a urologic
oncologist and multiple participants were actively
receiving treatment in her practice. She did not lead
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any sessions in order to allow participants to speak
freely about their experiences.
Data analysis
Transcript coding occurred from January through
March 2017 during monthly research team meetings.
As little is known about the NMIBC patient experi-
ence, we selected conventional content analysis to
code the transcripts [15]. This type of analysis is
used to describe a phenomenon that has not been
described before through the process of data immer-
sion. Four researchers (T.G., J.N.C., I.G.L., and
T.L.B.) under the direction of a qualitative research
expert (S.L.L.) read the transcripts carefully multi-
ple times, iteratively identified keywords and phrases,
and developed a limited preliminary code list. The
study team then discussed the preliminary list and
developed a mutually agreed upon codebook of over-
arching themes. Researchers then read each transcript
again and performed line-by-line coding. Disagree-
ments were discussed and resolved when possible.
There was high concordance between coders’ assess-
ments of key themes and phrases and the assignment
of content to categories. Consensus between focus
groups was reached early in the process.
RESULTS
Five primary themes emerged from analysis in-
cluding access to care, importance of provider charac-
teristics and communication, quality of life outcomes,
goals of care/influences on decision-making, and role
of social support (Table 1).
Access to care
Focus group participants expressed concerns about
gaining access to urologic care, both in terms of
care providers and treatment options. They noted
that it seemed difficult to recruit urologists. More
specifically, participants expressed concerns about
lack of continuity of care due to physician turnover.
They described difficulty obtaining timely appoint-
ments in the urology department after referral, and
worries about the impact of delayed care on cancer
progression. Participants wanted to have evaluation
and treatment close to home rather than traveling
long distances to major cities. Some individuals
had experienced the 2014 bacillus Calmette-Guerin
(BCG) shortage. They described receiving alternate
medications or reduced dosages of BCG which again
led to worry and stress. In relation to this, some were
worried about future access to standard of care treat-
ments for NMIBC due to national and international
drug shortages.
However, while most participants described access
barriers, one participant discussed how a single con-
tact person such as a nurse or patient navigator in the
urology department facilitated access.
Provider characteristics and communication
Focus group participants shared both positive
and negative experiences interacting with healthcare
providers such as urologists, advanced practition-
ers, and nursing staff. Most spoke very highly of
interactions with all healthcare providers; however,
some described poor experiences related to physi-
cian communication of the diagnosis. For example,
one participant received his/her bladder cancer diag-
nosis via secure email messaging from a physician
who was not one of his/her primary providers.
The groups felt that there was room for improve-
ment with the surveillance cystoscopy visits and that
the format of the visit did not leave time to discuss
the findings or other aspects of survivorship care such
as diet and lifestyle. Participants also expressed a
desire for prompt post-surgical communication with
providers after ambulatory surgery for transurethral
resection of bladder tumor (TURBT). They felt that
the time period between surgery and the visit to
discuss the pathology report was too long adding
unnecessarily to anxiety about results.
Participants described characteristics of high qual-
ity communication and praised providers who gave
thorough explanations about diagnostic tests and
treatments. Many participants wanted their providers
to render the diagnosis honestly and directly. They
felt that they needed to have confidence in the urol-
ogy provider and the healthcare system. Participants
were very appreciative of the hard work of nurses
and after-hours communications of physicians and
described how these actions made them feel special
and cared for.
Quality of life
One of the most significant themes to emerge was
how NMIBC treatments affected people’s lives both
physically and emotionally. A primary complaint was
changes in voiding habits due to the multiple TURBTs
and intravesical treatments. All three focus groups
reported frequency, urgency, and nocturia leading to
124 T. Garg et al. / Patient Experience in Non-Muscle Invasive Bladder Cancer
Table 1
Themes and subthemes with representative quotations
Themes and Subthemes Representative Quotations
1. Access to Care: Facilitators, Barriers, and Preferences
Barriers
-BCG Shortage • “she couldn’t get the [BCG] she wanted so she gave me 6 weeks of treatment of
some other medicine”
-Urologist Shortage
• “for me to wait a whole year for a doctor because they are so short of doctors in
this hospital and this is their complaint all the time they don’t have enough
doctors to take care of the patients. And I think the patient/doctor relationship is
really going down the drain because they are so busy and they can’t handle the
patients.”
Preferences • “I wanted to be here at Geisinger rather than hauling to Maryland or Philadelphia
or someplace like that.”
Facilitators of access • “A nurse essentially is what she is but she is sort of a. . . I don’t know if I am on
her caseload or whatever but she is my 1 contact at urology whenever I am about
to have a procedure or right after I have a procedure. If I have questions or
anything, I have always felt like there was a person there other than a doctor,
because you know how hard it is to get a doctor on the phone.”
2. Provider Characteristics and Communication
Good explanations of conditions • “And when I would go in for the scope every 3 months he would flip the camera
around and say now here is what I did here, here is what I did there and I’d say I
don’t think anybody could have explained it any better than he did.”
Honesty about diagnosis and treatment • “And he certainly wasn’t my friend. Very blunt. Very honest. Very truthful and
didn’t really sugar coat anything so. . . which personally I would rather have it
that way.”
Caring
-After-hours communication • “You know the calling at home. I had calls from Dr. X at home in the evening or
on the weekend and that is really important. I think it tells you that they really do
care and I know that probably all of us being the age we are that we recall the
family doctor that came to the home and made home visits. You don’t have that
today and it is an inconvenience in medical care today I think in some respects
and I think that the phone call really means a lot.”
-Appreciation for allied health & nursing staff
• “Well you have to give those poor nurses credit because those poor things just
run from one room to another. They do their job but they are on the go. I just
spent last Thursday in the hospital and I just got a card recently wishing me well
and there were 16 nurses that signed it.”
Importance of second opinions • “I think that second opinions are good. I think it allows the patient to really
realize and get a broader view of your condition and then the treatment for it and
so forth.”
Need for confidence in provider • “Attitude of the patient, confidence in the doctor and the entire Geisinger staff.
You have to have the confidence in there because that is a big thing to getting
better.”
Need for prompt post-surgical communication • “I would have liked to have had a follow-up after the surgery because right after
the surgery you can tell me anything you want and I’m not going to remember
it. . . so I think a follow-up call of some kind, either from the doctor or from
another knowledgeable person about me, because I would have had some
questions, “what did you find?”, “how bad was it?”
Poor interactions with providers • “I was very angry when I found out [about the cancer] because I found out via
email from a doctor who wasn’t even mine.”
• “It is kind of weird to go either once a year or every 6 months and all the doctor
does is insert a scope in you and look around and say “oh I don’t see anything”
or “oh I see something” and then see you in another 6 months. To me it’s not a
classic doctor/patient relationship. It’s sort of like there is no afterward
discussion about “here is what I saw” and then “what have you been doing?”
3. Impacts of Diagnosis and Treatment on Quality of Life
Concerns about hematuria • “I had 15 treatments of BCG and he said [the cancer] was clear. Every time I got
a treatment, I would hemorrhage bad.”
Difficulty with catheters • “I had to wear a big pair of baggy pants to my grandson’s graduation because
there was a bag there and I am feeling it every couple minutes to see if I have to
go to empty it. That was just hard. . . ”
(Continued)
T. Garg et al. / Patient Experience in Non-Muscle Invasive Bladder Cancer 125
Table 1
(Continued)
Themes and Subthemes Representative Quotations
Changes in urinary function • “I can’t go on a trip or anything. I have to know where the bathrooms are all the
time. Like I went down to see my daughter in Jersey last week. I stopped 6 times on
the way down. Finally, you know what I did? I stopped at McDonalds and picked up
a cup and believe me I used it. I had to, but you know you have to plan everything. I
can’t go anyplace without planning. I’ve got to make sure I have a bathroom.”
Poor sleep due to urinary function • “the only thing that changed is that before I had the bladder cancer and the surgery
and the treatments, I could go to sleep at night and get up the next morning and go to
the bathroom. Now it’s 2 or 3 times a night.”
Post-surgery side effects • “The cystoscopy was nothing. The after surgery stuff was brutal.”
• “That was the first major surgery that I have ever had. Ever since the surgery, I feel a
little differently. Like not my normal self. Kind of walking around in a dizzy state
for a little while.”
Fear, anxiety, and embarrassment • “And I had all sorts of fear. I never expected cancer.”
• “Yeah I don’t have fear either. I just go for my treatments and I just live like I don’t
have anything wrong.”
• “And I know nobody has really talked about this but when it has to do with your
penis and that whole area. . . I don’t know male or female it probably isn’t
something you really want to share with anybody about when there is something
wrong down there.”
4. Goals of Care and Influences on Treatment Decisions
Avoiding cystectomy • “Well, I didn’t want my bladder out. I decided I was not going to remove the bladder.
I had the idea that I would rather live with a bladder in and die sooner.”
• “We will go through almost anything instead of removal of the bladder from the
body. We lose sexual performance, that’s gone. And then the bag outside, which
is. . . we had the catheter with the bag and that was bad enough but to have it forever,
that is a situation that we have to look at. If we lose the bladder then we have to
carry the bag forever so we don’t want to lose that under any circumstances.”
• “What kind of bummed me out a little bit is how I have had the wash twice and each
time it was like they wanted to push to remove everything. I would say if my
lifestyle would allow it I probably would have went for it but my lifestyle. . . my
work. I really couldn’t go for a bag.”
Avoiding death • “I keep going from year to year but I really didn’t want surgery but I don’t want
cancer to take me either.”
• “I can see the point of, “yeah, we want to save your life.” We take everything out and
you are good.”
Being alive for family and other supporters • “I would rather get [the bladder] out and give me the satisfaction of knowing that it
is not there and not be scared and worried and crying every day because I have 12
granddaughters and 3 grandsons that I want to be with.”
5. Role of Social Support
Spouse, family, friends • “I’ll do my cooking and baking, my husband does the house work, he does the
laundry because I have trouble walking, especially in my spine area because of the
spinal stenosis and [friend] visited me and never left. But my family, my youngest
son and oldest son and husband I couldn’t ask for more.”
Other providers • “My own primary care physician, I speak to him about everything.”
Focus group • “This is now my support group. This is the only one that I have been to. I mean I
have learned some things tonight that when I go to urology now I will ask about.”
disrupted sleep and fatigue. Individuals described
challenges with travel or going out in public, need-
ing to find the nearest bathroom, and transitioning to
adultdiapers tomanagetheirurinarysymptoms.Addi-
tionalchallengesfollowingTURBTincludedpainand
changes in cognitive function. Discomfort with post-
operative catheters was universal. Hematuria was a
distressing side effect of intravesical treatment, and in
some instances, a complication after TURBT.
Emotional changes were noted beginning with
the diagnosis. Common reactions included expressed
embarrassment due to the close approximation of the
bladder to genitalia, as well as fear and “devastation”
when they found out they had cancer. Others were
matter-of-fact, feeling that fear was counterproduc-
tive to getting through treatment. Several participants
consciously transferred their fear to the healthcare
providers, stating that it was the providers’ job to
worry about the cancer, not theirs. Some described
how the diagnosis was something that could not be
changed, thus they put their fears aside in order to
focusontreatment.Levelsof fearwererelated toagein
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that younger participants (<60 years) described more
fear and devastation than older participants who were
grateful foreachdayandstoic regarding thediagnosis.
Goals of care and inﬂuences on treatment
decisions
Treatment decisions, and the factors that had
gone into them, were a major point of discussion,
especially in relation to radical cystectomy. There
was acknowledgement that radical cystectomy might
relieve the constant uncertainty of NMIBC recur-
rence, but most sought to avoid radical cystectomy at
all costs, even if it meant enduring the side effects of
multiple TURBTs and intravesical therapy. One par-
ticipant relayed the experience of someone in his/her
community who committed suicide after radical cys-
tectomy due to poor quality of life. Another felt that
having an ostomy would interfere with his/her liveli-
hood. Two participants expressed a willingness to
undergo radical cystectomy in order to prolong life
and be alive for family.
Role of social support
Support systems are critical to managing cancer
diagnosis and treatment. Spouses were identified as
the primary social support in all three focus groups.
Spouses helped participants quit smoking, make
dietary changes, and incorporate daily exercise. They
also kept track of appointments and medications,
and helped with household duties. Other supports,
such as grandchildren and friends provided comfort.
Additionally, adult children with medical or science
backgrounds were a resource for information gather-
ing about their condition.
Primary care and alternative medicine providers
were identified in all three groups as important
supports. A few participants had attended disease-
specific support groups and found them to be useful
for information gathering and obtaining support from
other patients. Those who had never attended a sup-
port group found participating in the focus group to
be a positive experience and in that being in this focus
group study for 1–2 hours was a support in itself.
DISCUSSION
Much of the current qualitative research in bladder
cancer is focused on the impact of major extirpa-
tive surgery for muscle invasive disease. However,
the majority of patients have NMIBC at diagnosis
and rarely progress to invasive disease. NMIBC has
its own set of challenges for patients including a
high recurrence rate, uncomfortable instrumentation
of the urinary tract for disease surveillance, frequent
outpatient surgeries, and treatment with intravesical
therapies. The effects of these challenges were cap-
tured via the experiences reported in this qualitative
focus group study of NMIBC patients. We identified
five common themes across the cancer continuum
including access to care, provider characteristics and
communication, quality of life, influences on treat-
ment decision-making/goals of care, and role of
social support.
Being treated for cancer is not a positive experi-
ence, but international studies suggest that the patient
experience for bladder cancer is especially poor. The
United Kingdom (UK) National Institute for Health
and Care Excellence (NICE) guidelines for bladder
cancer highlighted the phenomenon of low satisfac-
tion in this population [16]. The 2013 Cancer Patient
Experience Survey of 66,418 cancer patients from the
United Kingdom found that urologic cancer patients
(excluding prostate) scored lowest on twelve indi-
cators such as written assessments and care plans,
information about support groups, and contact infor-
mation for a clinical nurse specialist [16]. Bladder
cancer patients had the poorest satisfaction level with
treatment decision-making, resulting in a call to pur-
sue qualitative research to determine and address
causes [11].
Despite this, few studies have explored the causes
of poor patient experience in bladder cancer, espe-
cially in NMIBC. Our findings both corroborate
and expand upon limited existing qualitative stud-
ies. The study by Rutherford, et al. described how
side effects such as urgency, frequency, nocturia,
hematuria, and pain with urination influenced day-
to-day living such as social participation and travel,
cognitive function, and emotional well-being. The
importance of clear provider communication, support
from the healthcare system, and continuity of care
were also identified [17]. A recent mixed-methods
study with focus groups and surveys examining
attitudes towards surveillance cystoscopy in twelve
NMIBC patients in the Veterans Affairs system found
that NMIBC patients experienced anxiety around the
time of surveillance cystoscopy and have worry about
disease progression and metastasis. These patients,
similar to our study, had a wide range of perceptions
about their level of involvement with decisions about
surveillance from deferring to the physician to high
levels of involvement [18].
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Physician communication and decision-making
style is associated with a variety of outcomes in
cancer patients including trust and participation, self-
efficacy, perceived control, uncertainty, and mental
health-related quality of life [19]. A qualitative study
of bladder cancer patients from major cancer centers
described the importance of clear, compassionate,
and honest communication about treatment options,
side effects, and prognosis [20]. Another qualitative
study described how urologic cancer patients wanted
to be treated in a caring manner, as someone who mat-
ters [21]. Similarly, our participants’ valued provider
accessibility and caring attitudes. Teaching effective
and caring provider communication may be an impor-
tant target to improve patient experience, and is one
recommendation that has been implemented system-
wide at our institution and others through the C.I.
C.A.R.E model [22, 23].
A difference between our study and previous stud-
ies is the degree to which participants discussed
access to care. This likely reflects our rural setting.
While we are facing a nationwide urologist shortage,
rural areas are particularly hard-hit due to retirement
of older urologists and the preference of younger urol-
ogists to practice in urban areas [24]. In addition
to concern about the potential downstream effects
of diagnosis and treatment delays, our participants
desired care continuity and suggested having a single
point of contact or a navigator embedded within the
urology clinic. The UK NICE review found that this
intervention was associated with improved patient
satisfaction [16]. In addition to improving patient
satisfaction, patient navigator programs have been
shown to reduce health care utilization and costs. In
a study from the Centers for Medicare and Medicaid
(CMS), a patient navigator program was associ-
ated with fewer hospitalizations and emergency
department visits [25].
The patient perspective of the 2014 BCG shortage
was a timely finding, but oncology drug shortages
have been increasing [26]. To our knowledge, ours
is the only study to touch on the patient perspec-
tive of the BCG shortage, demonstrating both the
importance of steady access to lifesaving drugs and
uncertainty that can arise from intermittent access.
Social support was a significant theme in our
study and is associated with health-related quality
of life among cancer survivors [27]. Cancer sur-
vivors lacking a partner are more likely to report poor
physical and mental quality of life [28]. The previ-
ously described qualitative study of bladder cancer
patients from major cancer centers identified “family
issues” as a prominent theme in treatment decision-
making [20]. Family members had roles similar to
those elucidated in our study, including informa-
tion gathering and attendance at clinical encounters.
Our study highlights the fact that patients recognize
social support as an integral part of a successful
journey through the cancer continuum. Providers
should consider the social context around an indi-
vidual patient, and, when possible, seek partnerships
with informal caregivers to try to improve patient
experience.
The present study represents the first study to eval-
uate patient experience in NMIBC using qualitative
methods; however, our findings must be interpreted
within the context of certain limitations. We con-
ducted a limited number of focus groups with a
convenience sample of patients. It is possible we did
not reach thematic saturation and that with more focus
groups, we may have identified additional themes.
This study was conducted in a single, rural health
system and though most themes were similar to what
has previously been reported in the literature, we did
identify a few themes that may not be applicable
to patients in other health systems or in urban set-
tings. All of our participants were white, reflecting
the race/ethnicity of the GHS catchment area, and
thus the findings may not generalize to more diverse
populations.
This strengths of this study include its range of ages
and the enthusiastic engagement on the part of par-
ticipants. Previous studies were performed in urban,
academic medical centers. Our study, while it iden-
tified universal themes, also highlights the unique
perspectives of rural patients in community-based
healthcare systems. Finally, this is one of the few
existing studies that applies a qualitative approach
to understanding patient priorities and experience in
bladder cancer, and the largest focus group study
conducted in NMIBC [18].
CONCLUSIONS
In this qualitative study, we identified access to
care, provider characteristics and communication,
quality of life, values/influences on decision-making,
and social support as priority areas to improve patient
experience in NMIBC. Care redesign efforts should
focus on improving access, patient navigation and
care coordination, teaching providers caring commu-
nication, reducing side effects and emotional impacts,
and supporting the roles of informal caregivers.
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